Novo Nordisk wins a false-advertising ruling against an Ozempic copycat pharmacy

Novo Nordisk has won a false-advertising case against LifeRxMD Inc., a compounding pharmacy that sold copycat versions of its GLP-1 drugs. Judge Michael A. Shipp of the U.S. District Court for the District of New Jersey entered a final judgment on Sept. 2, 2026, closing out a roughly two-year advertising dispute after the two sides reached a confidential settlement ^[1][2].

Novo Nordisk had alleged that LifeRxMD's marketing falsely suggested its compounded products were genuine, FDA-approved or reviewed, or that they were associated with or equivalent to Novo Nordisk's brand-name drugs, which include Ozempic, Wegovy and Rybelsus. LifeRxMD denied the allegations ^[2].

Under the terms of the permanent injunction, LifeRxMD is barred from using Novo Nordisk's trademarks in certain ways when advertising or selling its compounded drugs ^[2]. As part of the settlement, LifeRxMD must conspicuously and prominently disclose in its marketing that its products have not been reviewed or approved by the FDA for safety and effectiveness ^[1]. For the next 12 months, the pharmacy must also disclose that the compounded drugs it sells are not FDA-approved or reviewed for safety, effectiveness or quality, and that FDA-approved semaglutide medicines are available ^[2].

The case is one of several legal actions brand-name GLP-1 makers have pursued in 2026 against companies selling compounded or unapproved versions of their drugs. Eli Lilly sued six companies in August over alleged sales of its unapproved investigational drug retatrutide and has referred more than 200 entities to federal and state authorities ^[2]. Novo Nordisk also settled a separate dispute with telehealth company Hims & Hers earlier this year. That case began in February, when Novo Nordisk sued Hims & Hers for patent infringement after the company started selling a compounded Wegovy pill; the two sides struck a partnership the following month ^[2].

Why it matters for patients

For people considering compounded semaglutide, this case is a reminder that not every product marketed alongside the names Ozempic, Wegovy or Rybelsus is the same as the FDA-approved medicine made by Novo Nordisk. The lawsuit centered on claims that a compounder's marketing made its product look genuine, approved or equivalent to the brand-name drug when it was not ^[2].

The disclosure requirements built into this settlement — spelling out that a compounded product has not been reviewed or approved by the FDA for safety and effectiveness, and noting that FDA-approved alternatives exist — are meant to give patients clearer information before they buy ^[1][2]. Patients weighing a compounded product versus a brand-name one may want to look for exactly this kind of disclosure, since it is now something at least one compounder is legally required to provide, at least for a period of 12 months ^[2].

The case does not address the safety or effectiveness of any specific compounded product; it was a dispute over advertising claims, not a determination about ingredients or manufacturing quality. What compounded semaglutide actually contains, and how it compares clinically to approved versions, is not addressed in this ruling and is not yet known from the sources here.

What happens next

The final judgment was entered Sept. 2, 2026, and LifeRxMD's 12-month disclosure obligation runs from that date ^[2]. Novo Nordisk and Eli Lilly have both signaled they intend to keep pursuing similar cases against compounders and other sellers of unapproved GLP-1 products, including Lilly's August lawsuit against six companies over retatrutide sales ^[2]. Whether other compounding pharmacies will face comparable injunctions or settlements is not detailed in these sources.